Thymosin Alpha-1: Molecular Structure

Molecular Structure#

Thymosin Alpha-1 (Ta1) is a linear 28-amino acid peptide with a molecular weight of 3108.3 daltons and the molecular formula C129H215N33O55. It was originally isolated from Thymosin Fraction 5, a partially purified extract of bovine thymus tissue, by Allan Goldstein and colleagues at the George Washington University School of Medicine in the 1970s. The peptide is encoded by the prothymosin alpha (PTMA) gene, from which it is proteolytically cleaved at the N-terminal region.

A defining structural feature of native Thymosin Alpha-1 is the N-terminal acetylation of the serine residue at position 1. This acetyl modification (Ac-Ser) is a co-translational modification that occurs in vivo and is preserved in the synthetic pharmaceutical form (thymalfasin/Zadaxin). The acetylation protects the peptide from aminopeptidase degradation and contributes to its biological activity and stability. Removal of the acetyl group has been shown to reduce immunomodulatory potency in functional assays.

Thymosin Alpha-1 adopts a predominantly unstructured, random coil conformation in aqueous solution, as demonstrated by circular dichroism (CD) spectroscopy and nuclear magnetic resonance (NMR) studies. Unlike globular proteins, Ta1 lacks a defined three-dimensional fold under physiological conditions, which is characteristic of intrinsically disordered proteins (IDPs). However, in the presence of membrane-mimetic environments such as trifluoroethanol (TFE) or sodium dodecyl sulfate (SDS) micelles, Ta1 can adopt partial alpha-helical structure, particularly in the central region spanning residues 14 to 26. This environment-dependent conformational flexibility may be relevant to its interactions with membrane-associated receptors.

The CAS registry number for Thymosin Alpha-1 is 62304-98-7, and the synthetic pharmaceutical form is designated by the International Nonproprietary Name (INN) thymalfasin.

Amino Acid Sequence#

The complete amino acid sequence of Thymosin Alpha-1 is:

Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn

The sequence is notable for its high proportion of acidic residues. Of the 28 amino acids, eight are negatively charged at physiological pH (five glutamic acid and two aspartic acid residues plus the C-terminal asparagine is neutral), while only three are positively charged (two lysine residues at positions 14 and 17, and one lysine at position 19 contribute to the three basic residues at positions 14, 17, 19, and 20). This yields a net negative charge at physiological pH 7.4, with a calculated isoelectric point (pI) of approximately 4.2. The strongly acidic character of Ta1 is a distinguishing feature among thymic peptides and influences its solubility, receptor binding, and pharmacokinetic behavior.

The amino acid composition lacks aromatic residues (no tryptophan, tyrosine, or phenylalanine), which means Ta1 has negligible UV absorbance at 280 nm. This property necessitates alternative analytical detection methods such as absorbance at 214 nm (peptide bond absorption) or mass spectrometry for quantification. The absence of cysteine residues means the peptide cannot form disulfide bonds, which contributes to its linear, unstructured conformation.

The sequence contains no sites for N-linked glycosylation (no Asn-X-Ser/Thr sequons) and no known post-translational modifications other than the N-terminal acetylation. The synthetic form of Ta1 is produced by solid-phase peptide synthesis and is chemically identical to the endogenous peptide.

Chemical Properties#

Thymosin Alpha-1 is freely soluble in aqueous solutions at physiological pH, consistent with its highly charged, hydrophilic amino acid composition. The peptide dissolves readily in water, phosphate-buffered saline (PBS), and dilute acetic acid. Its aqueous solubility exceeds 10 mg/mL at neutral pH.

The peptide is stable in lyophilized form when stored at controlled temperatures. In the pharmaceutical preparation (Zadaxin), lyophilized thymalfasin maintains potency for at least 24 months when stored at 2-8 degrees Celsius. Once reconstituted, the solution should be used within a limited timeframe, as the peptide is susceptible to degradation in aqueous solution over extended periods through deamidation of asparagine and glutamine residues and hydrolysis of aspartate-containing peptide bonds.

Degradation pathways for Ta1 in solution include:

• Deamidation: The asparagine residue at position 28 (C-terminal) is susceptible to deamidation, converting to aspartic acid or isoaspartic acid. This is the primary chemical degradation pathway and is accelerated at elevated temperatures and pH values above 6.
• Oxidation: Although Ta1 lacks methionine and cysteine residues (the amino acids most susceptible to oxidation), minor oxidative degradation can occur at other sites under stressed conditions.
• Hydrolysis: Asp-Pro and Asp-Gly bonds are the most labile to acid-catalyzed hydrolysis, though Ta1 lacks these specific dipeptide motifs. The Asp-Ala bond at positions 2-3 represents a potential, albeit relatively stable, hydrolysis site.

The synthetic manufacturing process for thymalfasin employs Fmoc-based solid-phase peptide synthesis (SPPS), followed by cleavage, purification by reversed-phase HPLC, and lyophilization. The N-terminal acetylation is introduced chemically during synthesis. Product quality is verified by mass spectrometry, amino acid analysis, HPLC purity assessment (greater than or equal to 98%), and endotoxin testing.

Pharmacokinetics#

The pharmacokinetic profile of Thymosin Alpha-1 has been characterized following subcutaneous administration, the approved clinical route for thymalfasin.

Absorption: Following subcutaneous injection of 1.6 mg thymalfasin, peak plasma concentrations (Cmax) are reached within approximately 2 hours (Tmax). The bioavailability after subcutaneous administration is estimated to be high, consistent with the peptide's small size and aqueous solubility. Plasma concentrations of Ta1 following a 1.6 mg dose typically reach peak levels in the range of 50-100 ng/mL, substantially above the endogenous baseline concentration of approximately 1-5 ng/mL observed in healthy individuals.

Distribution: Ta1 distributes into tissues including the spleen, thymus, lymph nodes, and other lymphoid organs. The relatively small molecular weight of 3108 daltons allows passage through capillary endothelium, though the peptide does not readily cross the blood-brain barrier. The volume of distribution has not been precisely determined from published pharmacokinetic studies, but the peptide's hydrophilic character suggests distribution primarily within the extracellular fluid compartment.

Metabolism and Elimination: Ta1 is eliminated primarily through renal filtration and enzymatic degradation by tissue and circulating peptidases. The elimination half-life following subcutaneous injection is approximately 2 hours, with plasma concentrations returning to near-baseline levels within 8 to 12 hours post-dose. The relatively short half-life supports the twice-weekly dosing regimen used in clinical practice, as the pharmacodynamic effects of immune cell activation and cytokine modulation persist substantially longer than the plasma presence of the peptide itself.

Endogenous Levels: Circulating levels of endogenous Ta1 vary with age, immune status, and disease state. Healthy young adults typically have serum Ta1 levels of 1-5 ng/mL, while levels decline with advancing age. Patients with chronic viral infections or immunodeficiency states may have altered baseline Ta1 levels. Thymic involution with aging is associated with progressive decline in endogenous Ta1 production, providing a rationale for exogenous supplementation in older adults.

Special Populations: No formal pharmacokinetic studies have been published in patients with hepatic or renal impairment. Given the renal route of elimination, dose adjustments may theoretically be warranted in patients with significant renal insufficiency, although clinical experience has not identified a need for modification in practice. The peptide is not expected to undergo hepatic metabolism through cytochrome P450 enzymes and thus has low potential for hepatic drug-drug interactions.

Pharmacokinetic-Pharmacodynamic Disconnect: A clinically important consideration for Thymosin Alpha-1 is the disconnect between its relatively short plasma half-life (approximately 2 hours) and the duration of its pharmacodynamic effects. The immunological actions of Ta1, including dendritic cell maturation, T-cell activation, and cytokine network modulation, persist for days to weeks after a single dose, as these reflect cellular programming events rather than continuous receptor occupancy. This property explains why a twice-weekly dosing schedule is effective despite rapid plasma clearance and why sustained virological responses in hepatitis B continue to improve for months after treatment cessation. The pharmacodynamic persistence is attributed to the durable phenotypic changes induced in immune cells, particularly the maturation of dendritic cells and the expansion of antigen-specific T-cell clones, processes that operate on timescales independent of circulating peptide levels.

Analytical Characterization#

Analytical identification and quality assessment of Thymosin Alpha-1 relies on several complementary techniques due to the peptide's unique properties, particularly its lack of aromatic amino acids and UV-absorbing chromophores at 280 nm.

Mass Spectrometry: Electrospray ionization mass spectrometry (ESI-MS) and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) are the primary methods for confirming peptide identity. The expected monoisotopic mass for acetylated Ta1 is 3107.4 Da, with the average molecular mass of 3108.3 Da. Mass spectrometry also confirms the presence of the N-terminal acetyl modification (42 Da mass addition compared to the unmodified sequence).

Reversed-Phase HPLC: High-performance liquid chromatography using C18 reversed-phase columns with UV detection at 214 nm (peptide bond absorbance) is the standard method for purity assessment. Pharmaceutical-grade thymalfasin requires HPLC purity of 98% or greater. The peptide's highly acidic character results in early elution relative to more hydrophobic peptides under standard gradient conditions.

Amino Acid Analysis: Quantitative amino acid analysis following acid hydrolysis provides compositional verification independent of sequence-specific methods. The characteristic amino acid ratios for Ta1 (particularly the high glutamic acid and aspartic acid content) serve as an identity fingerprint.

Circular Dichroism Spectroscopy: CD spectroscopy is used to assess secondary structure content. In aqueous buffer, Ta1 shows a CD spectrum characteristic of a random coil conformation, with a single minimum near 200 nm. In the presence of trifluoroethanol, the spectrum shifts to show minima at 208 nm and 222 nm, indicating alpha-helical content.

Related Reading#

• Thymosin Alpha-1 overview and research guide
• Peptides similar to Thymosin Alpha-1
• Thymosin Alpha-1 research evidence